Viewing StudyNCT04144517

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 1:51 PM
Last Modification Date: 2024-10-26 @ 1:21 PM
Study NCT ID: NCT04144517
Status: COMPLETED
Last Update Posted: 2024-01-25
First Post: 2019-10-24
Brief Title: A Study of ALKS 4230 Nemvaleukin Alfa With Pembrolizumab in Head and Neck Cancer
Sponsor: Mural Oncology Inc
Organization: Mural Oncology Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Non-cutaneous Squamous Cell Carcinoma of Head and Neck
Keywords:
Name View
Alkermes View
IL-2 View
Interleukin-2 View
Oncology View
Immuno-oncology View
Cytokine Immunotherapy View
ALKS 4230 View
Pembrolizumab View
Keytruda View
PD-L1 View
Solid Tumors View